A Republican bill with 11 Republican cosponsors · See all 11 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, titled the "Safeguarding Women from Chemical Abortion Act," aims to withdraw the approval of mifepristone for terminating intrauterine pregnancies. It stipulates that the approved application for this drug is deemed withdrawn under the Federal Food, Drug, and Cosmetic Act. Additionally, the act classifies the drug as misbranded if its labeling includes indications for pregnancy termination. The legislation also establishes a federal tort for harm caused by these medications. This allows individuals to seek damages for bodily injury or mental health harm resulting from the use of the drug.
Yes
No question was scored yes.
The opposite· 3 of 4
- Scored -10
Does this make abortion easier to get?
The bill deems the approval for mifepristone for pregnancy termination withdrawn, effectively removing access to the drug.
- Scored -8
Would women be better off under this?
The bill restricts a specific medical option for pregnancy termination and creates new litigation risks for reproductive health.
- Scored -5
Does this narrow the gap between how men and women are treated?
The bill restricts access to a medication used for reproductive healthcare, which disproportionately impacts women's autonomy.
Who it would affect, and how
Potential Positive Impacts for People
-
Establishment of a Federal Tort: This creates a legal pathway for individuals to seek compensation for bodily injury or mental health harm (including physical, psychological, emotional, or physiological harm) that is attributable to the use of mifepristone (Section 3(b)).
-
Right to Civil Action: Individuals who suffer harm may bring civil actions in a U.S. district court or a State court to recover compensatory damages, punitive damages, and attorney's fees and costs (Section 3(c)).
Potential Negative Impacts for People
-
Withdrawal of Drug Approval: The approved application for mifepristone used for the termination of intrauterine pregnancy is deemed withdrawn, which impacts the availability of the drug (Section 2(1)).
-
Classification as Misbranded: The drug is considered misbranded if the labeling provides that it may be used for the termination of intrauterine pregnancy or in conjunction with another drug for that purpose (Section 2(3)).
-
Legal Violations in Commerce: The introduction or delivery of the drug into interstate commerce will be considered a violation of the Federal Food, Drug, and Cosmetic Act once the approval is withdrawn (Section 2(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would women be better off under this? — The bill restricts a specific medical option for pregnancy termination and creates new litigation risks for reproductive health. Would households on low incomes be better off under this? — Reducing access to affordable medication for pregnancy termination can increase financial burdens on low-income individuals.
- Healthcare
- Does this make abortion easier to get? — The bill deems the approval for mifepristone for pregnancy termination withdrawn, effectively removing access to the drug.
- Social Issues And Justice
- Does this narrow the gap between how men and women are treated? — The bill restricts access to a medication used for reproductive healthcare, which disproportionately impacts women's autonomy.
- 9/1/2026
- 1 Cosponsor added.
- 8/31/2026
- 2 Cosponsors added.
- 5/21/2026
- 1 Cosponsor added.
- 5/14/2026
- 1 Cosponsor added.
- 4/22/2026
- 1 Cosponsor added.
- 3/24/2026
- 2 Cosponsors added.
- 3/20/2026
- 2 Cosponsors added.
- 3/18/2026
- 1 Cosponsor added.
- 3/12/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Mark AlfordRepublican · Missouri
Sheri BiggsRepublican · South Carolina
Andrew ClydeRepublican · Georgia
Neal DunnRepublican · Florida
Tracey MannRepublican · Kansas
Mary MillerRepublican · Illinois
Ralph NormanRepublican · South Carolina
John RoseRepublican · Tennessee
Christopher SmithRepublican · New Jersey
W. SteubeRepublican · Florida
Roger WilliamsRepublican · Texas